Alan F. Denenberg

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its common stock for up to an aggregate amount of $250 million…

Davis Polk advised the joint book-running managers on an SEC-registered debt offering by Alphabet Inc., consisting of $1 billion of 0.450% notes due 2025, $1 billion of 0.800% notes…

Davis Polk advised the underwriters in connection with an initial public offering of 11,000,000 shares of common stock of Nurix Therapeutics, Inc. at $19 per share, for total gross proceeds…

Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…

Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…

 Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by II-VI Incorporated of 10,697,570 shares of its common stock for an…

Davis Polk advised the representatives of the several underwriters in connection with the $296 million SEC-registered offering of 9,545,000 shares of common stock of 1Life Healthcare,…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Intuit Inc. of $500 million aggregate principal amount of 0.650% notes due 2023, …

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Zscaler, Inc. of $1.15 billion aggregate principal amount of its 0.125%…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…